Treatment of Budd-Chiari Syndrome Without Biochemical or Clinical Abnormalities and Without Signs of Portal Hypertension

This protocol addresses patients with Budd-Chiari syndrome who present asymptomatically — without biochemical or clinical abnormalities and without signs of portal hypertension. In this subset, hepatic venous congestion may be mild, absent, or compensated through alternative outflow routes.

Clinical situation

Asymptomatic patients in this group may not require interventional treatment. The absence of significant biochemical derangement and portal hypertension distinguishes their management from more advanced presentations of Budd-Chiari syndrome, and the approach is tailored accordingly.

Treatment approach (partial)

Given the underlying thrombophilic nature of the condition, a form of long-term anticoagulation therapy is central to management — though the specific agent selection in this population requires careful consideration.

The complete regimen, agent selection rationale, and monitoring considerations are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/diagnostics13081458

As also outlined in Figure 10, asymptomatic patients without biochemical and clinical abnormalities and without signs of portal hypertension may not require interventional treatment since congestion may be mild, absent, or compensated by other outflow routes.

Having a thrombophilic disease, most patients with BCS need lifelong anticoagulation medicine, which is accompanied with an increased risk of variceal bleeding of up to 17–50%.

View source ↗